Cbl Double Nickase Plasmid (h): sc-400561-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Cbl Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- Cbl Double Nickase Plasmid (h) and Cbl Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CBL. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Cbl Antibody (A-9): sc-1651
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cbl Double Nickase Plasmid (h) | sc-400561-NIC | 20 µg | $410.00 | |||
Cbl Double Nickase Plasmid (h2) | sc-400561-NIC-2 | 20 µg | $410.00 |
CBL encodes Cbl, an E3 ubiquitin ligase and adaptor protein that coordinates downregulation of activated receptor and non-receptor tyrosine kinases. Through its TKB domain and RING finger–dependent ubiquitination activity, Cbl promotes ubiquitin-mediated trafficking and degradation of signaling complexes, shaping outputs from pathways such as EGFR/RTK, MAPK/ERK, PI3K–AKT, and immune receptor signaling. Cbl also contributes to endocytosis, protein quality control, and feedback regulation of signal transduction intensity and duration. Dysregulation or mutation of CBL is linked to aberrant tyrosine kinase signaling and hematologic disease biology, making it a useful node for probing oncogenic signaling networks and immune cell regulatory circuits.
Cbl Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CBL locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CBL. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CBL function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CBL-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.